<DOC>
	<DOCNO>NCT02425722</DOCNO>
	<brief_summary>The objective study investigate dose-responses efficacy safety ASP0456 patient chronic constipation ( diagnosed Rome III criterion FC , include constipation due organic disease ) compare placebo investigate appropriate dose range P3 study .</brief_summary>
	<brief_title>A Study Evaluate Dose-responses Efficacy Safety ASP0456 Patient With Chronic Constipation</brief_title>
	<detailed_description>To determine optimum dose ASP0456 patient chronic constipation ( include constipation due organic disease ) Japan base efficacy safety , multicentered , placebo-controlled , double-blind , parallel group comparative study conduct . After two-week observation period , patient meet primary registration criterion randomize one five group start treatment period . The patient take daily orally breakfast two week .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Patient SBM* ( Spontaneous bowel movement ) less 3 time per week , six month prior provisional registration *Defecation without procedure laxative , suppository , enema , stool extraction day precede day defecation Patient affect one follow symptom six month provisional registration : Straining least 25 % defecation Lumpy hard stool least 25 % defecation Sensation incomplete evacuation least 25 % defecation Loose stool rarely present without use laxative six month prior provisional registration . Patients pancolonoscopy contrast enema ( sigmoidoscopy ) onset chronic constipation symptom organic change Patient meet IBSC diagnostic criterion Rome III six month prior provisional registration . Meaning patient recurrent abdominal pain discomfort least 3 days/month last 3 month associate two follow , patient affect follow IBS symptom six month prior provisional registration : Improvement defecation Onset associate change frequency stool Onset associate change form ( appearance ) stool Patient history surgical resection stomach , gallbladder , small intestine , large intestine ( exclude resection appendicitis benign polyp ) Patient history current affection inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Patient history current affection ischemic colitis Patient currently affect infectious enteritis Patient currently affect hyperthyroidism hypothyroidism Patient apparent mechanical obstruction ( i.e . patient ileus cause hernia ) Patient mega colon mega rectum Patient currently affect constipation due anorectal dysfunction Patient currently affect drug induce constipation . Patient constipation due organic disease Patient currently affect active peptic ulcer In case female , one currently affect endometriosis uterine adenomyosis Patient high depression anxiety consider influence drug evaluation Patient history abuse drug alcohol within year consent acquisition , current abuse Patient use underwent use undergo drug/therapy/test prohibit combine 3 day start bowel habit observation period ( Day 17 ) thereafter ( however , patient use underwent combinationrestricted drug/therapy accord Protocol may enrol provisionally ) Patient history current affection malignant tumor Patient currently affect serious cardiovascular disease , respiratory disease , kidney disease , hepatic disease , gastrointestinal disease ( exclude CC ) , hemorrhagic disease , neural/mental disease Patient history drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>ASP0456</keyword>
	<keyword>linaclotide</keyword>
	<keyword>chronic constipation</keyword>
</DOC>